Pinned Tweet
The PCCTC is now posting on Bluesky. Follow us there for innovative prostate cancer clinical trials updates: bsky.app/profile/thepcctc.bs…
📷
The PCCTC-managed @PCaPROMISE Registry will add to our understanding of how genetic differences affect patient outcomes, help family members understand their own risk of cancer, and guide discovery of new personalized treatments. To learn more visit prostatecancerpromise.org
We are pleased to announce our Summer 2025 internships in Data Management, Data Science, and Clinical Operations. Please direct anyone you know who is pursuing a career in clinical research or other health professions to the following link for more info
linkedin.com/posts/prostate-…
PCCTC investigators and colleagues collaborate on Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer (JCO Oncol Pract) pubmed.ncbi.nlm.nih.gov/3970…
PCCTC investigator Evan Y. Yu, MD (@UWDeptMedicine) discusses therapeutic goals of newly diagnosed metastatic hormone-sensitive prostate cancer via @TargetedOnc: targetedonc.com/view/newly-d…
An original investigation from PCCTC investigator @Daniel_J_George and colleagues, "Physician Reasons for or Against Treatment Intensification in Patients With Metastatic Prostate Cancer" published in JAMA Netw Open: jamanetwork.com/journals/jam…
The PCCTC retweeted
@ProstateNetwork invites all survivors, partners, and those helping in the fight to join us Wed December 4th 6:30 pm CST to learn about genetics from @KUCancerCenter & @ThePCCTC in person at @GildasClubKC 21 West 43rd KC, MO or simultaneously in our zoom bit.ly/3hvdbpf
The PCCTC retweeted
Hispanic patients more likely to be diagnosed with stage IV prostate cancer. Upwards to 30%. We need to do better. @UCSDCancer_COE @UCSDHealth @PCFnews @ThePCCTC @OncoAlert
The PCCTC retweeted
Join us during Men’s Health Awareness month for updates in prostate cancer treatments and our lessons learned from our Community Think Tank. Open to all patients and caregivers. @UCSDCancer @UCSDCancer_COE @PCFnews @ThePCCTC @UCSDHealth
The PCCTC retweeted
Register for the 3rd Annual Prostate Cancer Patient Summit hosted by @UCSDCancer @PCFnews na.eventscloud.com/website/7… on 1/31/2025-2/1/2025 at UCSD Park and Market.
The PCCTC retweeted
Case-based discussion on navigating the evolving landscape of castrate-resistant #ProstateCancer management. Oliver Sartor, MD @MayoClinic joins @DrRanaMcKay @UCSanDiego as part of an independent medical education initiative on UroToday > bit.ly/3VD9cOk @BayerPharma
New webinar now available! @OncologyInst recently partnered with @TrialLibrary for an impactful webinar, “Decentralized Community-Engaged Recruitment to a Prostate Cancer Registry Study.” docs.google.com/forms/d/e/1F…
The PCCTC retweeted
Neuroendocrine prostate cancer (NEPC) is a rare and aggressive subtype of prostate cancer.
@CaPsurvivorship & @sartor_oliver discussed options for patients with NEPC during our PCF Patient & Caregiver Virtual Summit on Advanced Prostate Cancer.
Watch: tinyurl.com/y9k29fvk
The PCCTC retweeted
Optimal imaging standards for #mCSPC. @morr316 @MSKCancerCenter joins @CaPsurvivorship @DanaFarber explaining how conventional imaging methods like PSA tracking are insufficient for monitoring disease progression in the era of adv ARSIs > bit.ly/460naNk
Now Hiring! The PCCTC is seeking an experienced Clinical Data Standards Manager to support our clinical research team. For details visit linkedin.com/jobs/view/40517…
The PCCTC retweeted
Very hopeful our STEAP1 CART from @fredhutch makes difference for patients with advanced CRPC!
🙏 @jklee_lab @vipulbhatia24 @theNCI #PromiCell for science and partnership.
@PCF_Science @TDorffOnc @neerajaiims @PGrivasMDPhD @morr316 @ThePCCTC
First-in-human phase I/II clinical trial of STEAP1 CAR T cell therapy for mCRPC now open to enrollment! NCT06236139 PI: @JessicaHawleyMD @fredhutch #NExT Program @NCItreatment
PCCTC Investigator @DrRanaMcKay (@UCSDHealth) named #LEAD2024 Woman Oncologist of the Year. Congratulations!
🏆 Congratulations to our inspirational #LEAD2024 Rising Star @NazliDizman and to our #LEAD2024 Woman Oncologist of the Year @DrRanaMcKay!
#WomenInMedicine
@WeAreWLO @MDAndersonNews @YaleIMed @cityofhope @montypal @ASCOTECAG
The PCCTC-managed @PCaPROMISE featured in CDMRP report on impactful #prostatecancer research to improve the lives of those affected cdmrp.health.mil/pcrp/resear…
PCCTC investigator @DRathkopf presents results from study of BMS-986365 (CC-94676) in heavily pretreated patients with mCRPC at #ESMO24
CC-94676-PCA-001: Clinical activity of BMS-986365, a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with #mCRPC. Presentation by @DRathkopf @MSKCancerCenter. Presentation by @zklaassen_md @GACancerCenter > bit.ly/4gt0IkU
